fluticasone propionate and salmeterol

FDA Drug Profile — fluticasone propionate and salmeterol, ADVAIR DISKUS, Fluticasone Propionate and Salmeterol DISKUS, Wixela Inhub, Fluticasone Propionate and Salmeterol

fluticasone propionate and salmeterol is listed in the FDA National Drug Code directory with 41 NDC codes, marketed under brand names including fluticasone propionate and salmeterol, ADVAIR DISKUS, Fluticasone Propionate and Salmeterol DISKUS. Available dosage form: powder.

Drug details

Generic Name
fluticasone propionate and salmeterol
Brand Names
fluticasone propionate and salmeterol, ADVAIR DISKUS, Fluticasone Propionate and Salmeterol DISKUS, Wixela Inhub, Fluticasone Propionate and Salmeterol
Application Number
ANDA203433
Sponsor
Hikma Pharmaceuticals USA Inc.
NDC Codes
41
Dosage Forms
POWDER
Routes
RESPIRATORY (INHALATION)
Active Ingredients
SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE

Indications and Usage

1 INDICATIONS AND USAGE Fluticasone Propionate/Salmeterol DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: Twice-daily treatment of asthma in patients aged 4 years and older. ( 1.1 ) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). ( 1.2 ) Important limitation of use: Not indicated for relief of acute bronchospasm. ( 1.1 , 1.2 ) 1.1 Treatment of Asthma Fluticasone Propionate/Salmeterol DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. Fluticasone Propionate/Salmeterol DISKUS should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta 2 -adrenergic agonist (LABA). Important Limitation of Use Fluticasone Propionate/Salmeterol DISKUS is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Chronic Obstructive Pulmonary Disease Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength Fluticasone Propionate/Salmeterol DISKUS inhalation powder 500/50 mcg over Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg has not been demonstrated. Important Limitation of Use Fluticasone Propionate/Salmeterol DISKUS is NOT indicated for the relief of acute bronchospasm.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.